Founded in 2021, Ray Therapeutics is a clinical-stage biotechnology company developing best-in-class vision restoration therapies for people with degenerative retinal diseases independent of genetic mutation. Our highly-experienced management team is making a difference in the lives of people with blinding diseases in ways previously unimagined.
Vision loss affects millions of people worldwide, yet no treatments currently exist to restore sight once it is lost. For those living with blinding diseases, the loss of vision often means losing independence, connection, and the ability to experience life fully.
Inspired to find a new trajectory for these life-altering diseases, we saw the promise of applying optogenetics—a mature and well-studied technology—to address the unmet needs of people with low vision. Our goal: to develop an elegant approach to restoring lost vision through single-dose treatments, delivered through a simple procedure, to people with blinding diseases regardless of genetic mutation.
We’re committed to realizing the promise of optogenetics technology for vision restoration. Knowing that patients currently have no options fuels our sense of urgency and responsibility.
“As the parent of a child with a blinding disease, I personally know the challenges of vision loss and the very high unmet need for restorative therapies. I saw optogenetics as a proven technology that could be used, for the first time, to restore sight.”
PAUL BRESGE
Chief Executive Officer
©2025 Ray Therapeutics, Inc. All Rights Reserved.
Design by The Grace Communication Group.
